Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update
June 17, 2019 07:30 ET
|
Voyager Therapeutics, Inc.
Gains worldwide rights to VY-HTT01 for Huntington’s disease Resources to be reallocated to VY-HTT01 and other programs; intends to seek a partner for the SOD1 ALS program CAMBRIDGE, Mass., June 17,...
uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
May 22, 2019 07:00 ET
|
uniQure Inc.
~ Issued Patents in the U.S. and EU Cover RNA Construct Specifically Designed to Target Highly Toxic Exon1 Protein ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 22, 2019 (GLOBE NEWSWIRE)...
uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
May 07, 2019 07:00 ET
|
uniQure Inc.
~ Data Show AMT-150 Able to Significantly Lower Mutant Ataxin-3 Protein in SCA3 Disease Model ~ ~ Provides Further Support of Proof-of-concept of Company’s Proprietary miQURE™ Gene Silencing...
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
April 08, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
February 27, 2019 07:00 ET
|
uniQure Inc.
~ AMT-130 Shows Restoration of Brain Cell Function and Reversal of Neuropathology in Huntington’s Disease Mouse Model ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2019 (GLOBE...
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
January 22, 2019 07:00 ET
|
uniQure Inc.
~ AMT-130 Poised to Become First AAV Gene Therapy to Enter the Clinic for Huntington’s Disease ~ ~ Lead Product Candidate from Company’s Proprietary miQURE™ Gene Silencing Platform ~ LEXINGTON,...
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
November 07, 2018 16:10 ET
|
Voyager Therapeutics, Inc.
One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and beyond from ongoing Phase 1b trial Recent preclinical results for Huntington’s disease and...
Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
October 16, 2018 07:03 ET
|
Voyager Therapeutics, Inc.
One-time delivery of VY-HTT01 for Huntington’s disease achieves significant reduction of HTT gene expression in deeper tissues and outer layers of the brain of large animals One-time delivery of...
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
August 08, 2018 07:00 ET
|
uniQure Inc.
~ Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061 ~ First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061 ~ Robert Gut, M.D., Ph.D.,...
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights
August 07, 2018 16:07 ET
|
Voyager Therapeutics, Inc.
Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson’s disease Pipeline programs progressing with updated preclinical data from...